RAISING is a high-performance method for identifying random transgene integration sites.


Journal

Communications biology
ISSN: 2399-3642
Titre abrégé: Commun Biol
Pays: England
ID NLM: 101719179

Informations de publication

Date de publication:
02 06 2022
Historique:
received: 14 05 2021
accepted: 09 05 2022
entrez: 2 6 2022
pubmed: 3 6 2022
medline: 7 6 2022
Statut: epublish

Résumé

Both natural viral infections and therapeutic interventions using viral vectors pose significant risks of malignant transformation. Monitoring for clonal expansion of infected cells is important for detecting cancer. Here we developed a novel method of tracking clonality via the detection of transgene integration sites. RAISING (Rapid Amplification of Integration Sites without Interference by Genomic DNA contamination) is a sensitive, inexpensive alternative to established methods. Its compatibility with Sanger sequencing combined with our CLOVA (Clonality Value) software is critical for those without access to expensive high throughput sequencing. We analyzed samples from 688 individuals infected with the retrovirus HTLV-1, which causes adult T-cell leukemia/lymphoma (ATL) to model our method. We defined a clonality value identifying ATL patients with 100% sensitivity and 94.8% specificity, and our longitudinal analysis also demonstrates the usefulness of ATL risk assessment. Future studies will confirm the broad applicability of our technology, especially in the emerging gene therapy sector.

Identifiants

pubmed: 35654946
doi: 10.1038/s42003-022-03467-w
pii: 10.1038/s42003-022-03467-w
pmc: PMC9163355
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

535

Subventions

Organisme : NIAMS NIH HHS
ID : T32 AR060719
Pays : United States

Informations de copyright

© 2022. The Author(s).

Références

Br J Haematol. 1991 Nov;79(3):428-37
pubmed: 1751370
Lancet. 1986 May 3;1(8488):1031-2
pubmed: 2871307
Nat Biotechnol. 2015 Feb;33(2):187-197
pubmed: 25513782
Dev Dyn. 2014 Dec;243(12):1632-6
pubmed: 25160973
J Virol. 1995 Jun;69(6):3712-20
pubmed: 7745720
Nat Methods. 2007 Dec;4(12):1051-7
pubmed: 18049469
Nat Med. 2009 Dec;15(12):1431-6
pubmed: 19966782
Blood. 2017 Mar 2;129(9):1071-1081
pubmed: 28115366
Genome Med. 2014 Jun 27;6(6):46
pubmed: 25028597
Nat Genet. 2015 Nov;47(11):1304-15
pubmed: 26437031
Int J Hematol. 2020 Sep;112(3):300-306
pubmed: 32725607
Proc Natl Acad Sci U S A. 2020 May 26;117(21):11685-11691
pubmed: 32393644
Clin Immunol. 1999 Jun;91(3):321-9
pubmed: 10370378
Nat Commun. 2017 May 23;8:15264
pubmed: 28534499
Appl Transl Genom. 2016 Mar 10;9:15-9
pubmed: 27354935
N Engl J Med. 2002 Apr 18;346(16):1185-93
pubmed: 11961146
Front Microbiol. 2012 Nov 15;3:388
pubmed: 23162541
Cell Rep. 2019 Oct 15;29(3):724-735.e4
pubmed: 31618639
J Clin Microbiol. 2015 Nov;53(11):3485-91
pubmed: 26292315
Leukemia. 2021 Mar;35(3):764-776
pubmed: 32555298
BMC Genomics. 2018 May 2;19(1):318
pubmed: 29720086
Lancet. 1985 Aug 24;2(8452):407-10
pubmed: 2863442
Blood. 2020 Jun 4;135(23):2023-2032
pubmed: 32160278
BMC Bioinformatics. 2019 Jul 25;20(1):405
pubmed: 31345161
J Clin Microbiol. 2015 Feb;53(2):587-96
pubmed: 25502533
Mol Ther Nucleic Acids. 2015 Nov 17;4:e264
pubmed: 26575098
J Exp Med. 1985 Dec 1;162(6):2169-74
pubmed: 2866223
Br J Haematol. 2005 Jan;128(2):253-65
pubmed: 15638862
Proc Natl Acad Sci U S A. 1980 Dec;77(12):7415-9
pubmed: 6261256
Nat Protoc. 2010 Aug;5(8):1379-95
pubmed: 20671722
Mol Ther Nucleic Acids. 2019 Jun 7;16:326-334
pubmed: 30965277
Blood. 2011 Mar 17;117(11):3113-22
pubmed: 21228324
Nat Rev Cancer. 2010 Dec;10(12):878-89
pubmed: 21102637
J Gen Virol. 1977 Jul;36(1):59-74
pubmed: 886304
Blood. 2002 Jan 1;99(1):88-94
pubmed: 11756157
CRISPR J. 2018 Jun;1:239-250
pubmed: 31021262
Proc Natl Acad Sci U S A. 1981 Oct;78(10):6476-80
pubmed: 7031654
Nat Genet. 2015 Feb;47(2):158-63
pubmed: 25581428
AIDS Res Hum Retroviruses. 2013 Feb;29(2):359-64
pubmed: 22894552
EBioMedicine. 2018 Aug;34:18-26
pubmed: 30082227
N Engl J Med. 2004 Feb 26;350(9):913-22
pubmed: 14985489
J Infect Dis. 2002 Oct 1;186(7):932-9
pubmed: 12232833
J Neurovirol. 1998 Dec;4(6):586-93
pubmed: 10065900
Nat Commun. 2013;4:2513
pubmed: 24085110
Blood. 2010 Aug 26;116(8):1211-9
pubmed: 20448111

Auteurs

Yusaku Wada (Y)

Biotechnological Research Support Division, FASMAC Co., Ltd, Atsugi, Kanagawa, 243-0021, Japan.

Tomoo Sato (T)

Department of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Kanagawa, 216-8512, Japan.
Division of Neurology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Kanagawa, 216-8511, Japan.

Hiroo Hasegawa (H)

Department of Laboratory Medicine, Nagasaki University Hospital, Nagasaki, 852-8501, Japan.
Department of Laboratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, 852-8501, Japan.

Takahiro Matsudaira (T)

Biotechnological Research Support Division, FASMAC Co., Ltd, Atsugi, Kanagawa, 243-0021, Japan.

Naganori Nao (N)

Division of International Research Promotion, International Institute for Zoonosis Control, Hokkaido University, Sapporo, 001-0020, Japan.
One Health Research Center, Hokkaido University, Sapporo, 060-0818, Japan.

Ariella L G Coler-Reilly (ALG)

Department of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Kanagawa, 216-8512, Japan.
Department of Internal Medicine, Division of Bone and Mineral Diseases, Washington University School of Medicine, St. Louis, MO, 63110, USA.

Tomohiko Tasaka (T)

Affinity Science Corporation, Tokyo, 141-0031, Japan.

Shunsuke Yamauchi (S)

Department of Laboratory Medicine, Nagasaki University Hospital, Nagasaki, 852-8501, Japan.

Tomohiro Okagawa (T)

Department of Advanced Pharmaceutics, Faculty of Veterinary Medicine, Hokkaido University, Hokkaido, 060-0818, Japan.

Haruka Momose (H)

Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Tokyo, 208-0011, Japan.

Michikazu Tanio (M)

Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Tokyo, 208-0011, Japan.

Madoka Kuramitsu (M)

Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Tokyo, 208-0011, Japan.

Daisuke Sasaki (D)

Department of Laboratory Medicine, Nagasaki University Hospital, Nagasaki, 852-8501, Japan.

Nariyoshi Matsumoto (N)

Department of Laboratory Medicine, Nagasaki University Hospital, Nagasaki, 852-8501, Japan.

Naoko Yagishita (N)

Department of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Kanagawa, 216-8512, Japan.

Junji Yamauchi (J)

Department of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Kanagawa, 216-8512, Japan.

Natsumi Araya (N)

Department of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Kanagawa, 216-8512, Japan.

Kenichiro Tanabe (K)

Pathophysiology and Bioregulation, St. Marianna University Graduate School of Medicine, Kawasaki, Kanagawa, 216-8511, Japan.

Makoto Yamagishi (M)

Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, 108-8639, Japan.

Makoto Nakashima (M)

Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, 108-8639, Japan.

Shingo Nakahata (S)

Division of Tumor and Cellular Biochemistry, Department of Medical Sciences, University of Miyazaki, Miyazaki, 889-1692, Japan.

Hidekatsu Iha (H)

Department of Microbiology, Faculty of Medicine, Oita University, Oita, 879-5593, Japan.

Masao Ogata (M)

Department of Hematology, Oita University Hospital, Oita, 879-5593, Japan.

Masamichi Muramatsu (M)

Department of Virology II, National Institute of Infectious Diseases, Tokyo, 162-8640, Japan.

Yoshitaka Imaizumi (Y)

Department of Hematology, Nagasaki University Hospital, Nagasaki, 852-8501, Japan.

Kaoru Uchimaru (K)

Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, 108-8639, Japan.

Yasushi Miyazaki (Y)

Department of Hematology, Nagasaki University Hospital, Nagasaki, 852-8501, Japan.
Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, 852-8102, Japan.

Satoru Konnai (S)

Department of Advanced Pharmaceutics, Faculty of Veterinary Medicine, Hokkaido University, Hokkaido, 060-0818, Japan.
Department of Disease Control, Faculty of Veterinary Medicine, Hokkaido University, Sapporo, Hokkaido, 060-0818, Japan.

Katsunori Yanagihara (K)

Department of Laboratory Medicine, Nagasaki University Hospital, Nagasaki, 852-8501, Japan.
Department of Laboratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, 852-8501, Japan.

Kazuhiro Morishita (K)

Division of Tumor and Cellular Biochemistry, Department of Medical Sciences, University of Miyazaki, Miyazaki, 889-1692, Japan.

Toshiki Watanabe (T)

Department of Practical Management of Medical Information, St. Marianna University Graduate School of Medicine, Kawasaki, Kanagawa, 216-8511, Japan.

Yoshihisa Yamano (Y)

Department of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Kanagawa, 216-8512, Japan.
Division of Neurology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Kanagawa, 216-8511, Japan.

Masumichi Saito (M)

Department of Virology II, National Institute of Infectious Diseases, Tokyo, 162-8640, Japan. saitomas@niid.go.jp.
Center for Emergency Preparedness and Response, National Institute of Infectious Diseases, Tokyo, 162-8640, Japan. saitomas@niid.go.jp.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH